Featured Research

from universities, journals, and other organizations

Brain-gut Relationship In Those Suffering With Stomach Pain Or Discomfort To Be Studied

Date:
September 6, 2007
Source:
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Summary:
A new clinical study will explore the brain-gut interaction in patients with functional dyspepsia and whether certain drugs can effectively relieve symptoms of this disorder. Functional dyspepsia is a costly and chronic disorder that can cause severe stomach pain often reported as cramping, bloating and gas, or great discomfort or fullness after eating.

A new clinical study will explore the brain-gut interaction in patients with functional dyspepsia and whether certain drugs can effectively relieve symptoms of this disorder. Functional dyspepsia is a costly and chronic disorder that can cause severe stomach pain often reported as cramping, bloating, and gas, or great discomfort or fullness after eating.

The Functional Dyspepsia Treatment Trial (FDTT) will determine if either of two FDA-approved drugs that act on both the brain and the gut are better than placebo in relieving stomach pain, or discomfort after meals, in patients with functional dyspepsia. The study will also determine whether certain genes can predict who will best respond or not respond to the medicines. Finally, the trial will determine whether participants have a continued response for six months after the medicines are stopped.

Functional dyspepsia is a commonly diagnosed disorder. The symptoms are thought to be the result of abnormal muscle activity within the stomach, which may be caused by abnormal sensitivity of the nerves in the stomach or irregular signals from the brain to the muscles in the gut. "While we do not know the exact cause of functional dyspepsia, we do know that the disorder can cause chronic and sometimes debilitating symptoms that can have a dramatic effect on the quality of life for functional dyspepsia suffers," said Patricia Robuck, Ph.D., M.P.H., project scientist for FDTT and director of the Clinical Trials Program of the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the sponsor of the FDTT at NIH. "We are interested in learning more about the brain-gut interaction and physiological effects of these two similar but different classes of drugs on the symptoms associated with functional dyspepsia."

Currently, the treatment of functional dyspepsia is considered limited. Standard treatment includes food restriction and antisecretory drugs (H2 blockers, proton pump inhibitors) and prokinetics, which help make the stomach empty faster. Patients with dyspepsia sometimes also try alternative medicines and non-drug measures such as hypnotherapy. The effectiveness of these alternative measures remains unproven.

Results from small studies using medications like amitriptyline and escitalopram for adults with functional dyspepsia suggest that the abdominal pain and motility may get better. "We are excited by these early findings," says Nicholas J. Talley, M.D., Ph.D., chair of the trial and Chair of the Department of Internal Medicine at the Mayo Clinic, Jacksonville, Florida. "If it turns out that these drugs correct stomach emptying, stomach retention, and overall motility, we could help improve the quality of health and life for the millions of people with functional dyspepsia."

Over the next five years, researchers will enroll 400 men and women, ages 18-75 years old with functional dyspepsia who have failed to respond to antisecretory treatments for the disorder. The participants will receive amitriptyline, or escitalopram, or placebo. Patients with peptic ulcer disease, a history of drug or alcohol abuse, and past abdominal surgeries will be excluded from the trial. Women who are pregnant and patients whose reading skills are insufficient to complete self report questionnaires will also be excluded. Recruitment for the trial began in January, 2007.

The study is funded by the National Institutes of Health (NIH) at six medical centers in the U.S.


Story Source:

The above story is based on materials provided by NIH/National Institute of Diabetes and Digestive and Kidney Diseases. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute of Diabetes and Digestive and Kidney Diseases. "Brain-gut Relationship In Those Suffering With Stomach Pain Or Discomfort To Be Studied." ScienceDaily. ScienceDaily, 6 September 2007. <www.sciencedaily.com/releases/2007/09/070905161414.htm>.
NIH/National Institute of Diabetes and Digestive and Kidney Diseases. (2007, September 6). Brain-gut Relationship In Those Suffering With Stomach Pain Or Discomfort To Be Studied. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2007/09/070905161414.htm
NIH/National Institute of Diabetes and Digestive and Kidney Diseases. "Brain-gut Relationship In Those Suffering With Stomach Pain Or Discomfort To Be Studied." ScienceDaily. www.sciencedaily.com/releases/2007/09/070905161414.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins